title: HPV16-L1-specific antibody response is associated with clinical remission of high-risk HPV-positive early dysplastic lesions.
abstract: OBJECTIVE
  The present study was aimed at clarifying if use of a rapid human papillomavirus type 16 L1-specific antibody test could be used to improve clinical management of high-risk HPV-positive low-grade squamous intraepithelial lesion (LSIL)/high-grade squamous intraepithelial lesion (HSIL).
  
  
  METHODS
  The study was nested within a prospective study of 801 patients with early dysplastic high-risk HPV-positive lesions to examine the prognostic significance of HPV-L1 protein detection. Serum samples of 87 patients were tested with a rapid HPV16-L1-specific antibody test. The results were correlated with the clinical outcome during 66 months of follow-up.
  
  
  RESULTS
  A combined analysis of the 22 antibody-positive women showed that 17 were also L1 protein-positive, and 5 were L1 capsid protein-negative. An HPV-specific immune competence strongly correlates with clinical remission of low-grade squamous intraepithelial lesion (76.6%). For L1 antigen and HPV16-L1 antibody double-positive women, the risk of progression to cervical intraepithelial neoplasia grade 3 was low (5.8%).
  
  
  CONCLUSIONS
  The rapid anti-HPV16-L1 test could be a promising tool to improve risk assessment and appropriate clinical management of high-risk HPV-positive early dysplastic lesions.
authors.affiliation: Department of Gynecology, Erlangen University Hospital, Erlangen, Germany grit.mehlhorn@uk-erlangen.de.
authors.forename: Grit
authors.initials: G
authors.lastname: Mehlhorn
authors.affiliation: Department of Gynecology, Erlangen University Hospital, Erlangen, Germany.
authors.forename: Simone K
authors.initials: SK
authors.lastname: Hautmann
authors.affiliation: Department of Gynecology, Erlangen University Hospital, Erlangen, Germany.
authors.forename: Martin C
authors.initials: MC
authors.lastname: Koch
authors.affiliation: Institute of Pathology, Erlangen University Hospital, Erlangen, Germany.
authors.forename: Johanna D
authors.initials: JD
authors.lastname: Strehl
authors.affiliation: Institute of Pathology, Erlangen University Hospital, Erlangen, Germany.
authors.forename: Arndt
authors.initials: A
authors.lastname: Hartmann
authors.affiliation: Cytoimmun-Diagnostics GmbH, Pirmasens, Germany.
authors.forename: Ralf
authors.initials: R
authors.lastname: Hilfrich
authors.affiliation: Department of Gynecology, Erlangen University Hospital, Erlangen, Germany.
authors.forename: Matthias W
authors.initials: MW
authors.lastname: Beckmann
authors.affiliation: Department of Pathology and Cytodiagnostics, Laboratory Medicine, Cologne, Germany.
authors.forename: Henrik
authors.initials: H
authors.lastname: Griesser
mesh_terms: D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000276:immunology*; D036022:Capsid Proteins / Q000235:genetics / Q000276:immunology*; D016022:Case-Control Studies; D005260:Female; D005500:Follow-Up Studies; D052162:Human papillomavirus 16 / Q000276:immunology; D006801:Humans; D008875:Middle Aged; D009856:Oncogene Proteins, Viral / Q000235:genetics / Q000276:immunology*; D011379:Prognosis; D011446:Prospective Studies; D012074:Remission Induction; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000276:immunology* / Q000473:pathology / Q000628:therapy / Q000821:virology*; D055815:Young Adult; D002578:Uterine Cervical Dysplasia / Q000276:immunology* / Q000473:pathology / Q000628:therapy / Q000821:virology*
chemical_list: D000914:Antibodies, Viral; D036022:Capsid Proteins; D009856:Oncogene Proteins, Viral; C063317:L1 protein, Human papillomavirus type 16
keywords: CIN; Cervical intraepithelial neoplasia; HPV L1 capsid protein; HPV16-specific antibody; high-risk HPV-positive